Workflow
总市值
icon
Search documents
泰山石油收盘上涨1.82%,滚动市盈率26.10倍,总市值34.91亿元
Sou Hu Cai Jing· 2025-08-26 08:22
8月26日,泰山石油今日收盘7.26元,上涨1.82%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到26.10倍,创46天以来新低,总市值34.91亿元。 来源:金融界 中国石化山东泰山石油股份有限公司的主营业务是成品油批发零售业务以及非油品业务。公司的主要产 品是汽油、柴油、天然气、其他。 最新一期业绩显示,2025年一季报,公司实现营业收入8.02亿元,同比-4.76%;净利润5296.57万元,同 比185.74%,销售毛利率17.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8泰山石油26.1035.143.2034.91亿行业平均 12.0011.801.231858.61亿行业中值23.3633.371.7164.59亿1中国海油9.178.961.5812357.79亿2中国石油 9.699.751.0316050.94亿3广汇能源12.3011.831.27350.28亿4*ST新潮14.1213.961.24284.26亿5中国石化 19.5514.030.857056.47亿6沈阳化工19.92-21.222.4635.65亿7洲际油气23.3620.76 ...
维力医疗收盘上涨1.03%,滚动市盈率18.44倍,总市值43.23亿元
Sou Hu Cai Jing· 2025-08-25 11:30
Core Viewpoint - Weili Medical's stock closed at 14.76 yuan, with a rolling PE ratio of 18.44 times, significantly lower than the industry average of 55.91 times, indicating potential undervaluation in the medical device sector [1][2] Company Summary - Weili Medical specializes in the research, production, and sales of medical catheters in fields such as anesthesia, urology, respiration, and hemodialysis [1] - The company's main products include tracheal intubation, laryngeal masks, bronchial intubation, visual bronchial intubation, tracheostomy tubes, anesthesia masks, artificial noses, anesthesia breathing circuits, electronic analgesia pumps, urinary catheters, drainage bags, and various other specialized medical devices [1] Financial Performance - For the first half of 2025, Weili Medical reported revenue of 745 million yuan, a year-on-year increase of 10.19% [1] - The net profit for the same period was 121 million yuan, reflecting a year-on-year growth of 14.17% [1] - The company's gross profit margin stood at 45.04% [1] Institutional Holdings - As of the 2025 semi-annual report, 16 institutions held shares in Weili Medical, including 8 funds, 6 other institutions, 1 social security fund, and 1 insurance company, with a total holding of 161.66 million shares valued at 2.056 billion yuan [1]
乐惠国际收盘上涨1.52%,滚动市盈率130.37倍,总市值34.69亿元
Sou Hu Cai Jing· 2025-08-25 11:13
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Lehui International, with a current PE ratio of 130.37, which is significantly higher than the industry average of 82.52 [1][2] - As of March 31, 2025, Lehui International has 8,564 shareholders, a decrease of 629 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and manufacturing of liquid food equipment, with key products including brewing equipment and sterile filling equipment, recognized as national champions in their category [1] Group 2 - In the latest quarterly report for Q1 2025, Lehui International reported a revenue of 206 million yuan, a year-on-year decrease of 5.87%, while net profit increased by 160.61% to 8.94 million yuan, with a gross margin of 20.66% [1] - The company ranks 220th in the industry based on PE ratio, indicating a relatively high valuation compared to its peers [1][2] - The average PE ratio for the specialized equipment industry is 82.52, with a median of 60.21, suggesting that Lehui International's valuation is significantly above the industry norms [2]
江河集团收盘上涨2.21%,滚动市盈率14.81倍,总市值88.94亿元
Sou Hu Cai Jing· 2025-08-25 11:06
Group 1 - The core viewpoint of the articles highlights Jianghe Group's current stock performance, with a closing price of 7.85 yuan, an increase of 2.21%, and a rolling PE ratio of 14.81, marking a new low in 18 days, with a total market value of 8.894 billion yuan [1] - Jianghe Group operates primarily in the construction decoration and healthcare sectors, with key products including building curtain walls, photovoltaic buildings, interior decoration, interior design, and ophthalmic medical services [1] - As of the first quarter of 2025, Jianghe Group reported a revenue of 4.203 billion yuan, a year-on-year increase of 2.87%, and a net profit of 144 million yuan, reflecting a year-on-year decrease of 20.53%, with a sales gross margin of 15.03% [1] Group 2 - In terms of industry comparison, Jianghe Group's PE ratio of 14.81 is significantly lower than the industry average of 62.24 and the industry median of 81.86, ranking 21st among its peers [2] - The company has seven institutional holders, all of which are funds, collectively holding 7.4378 million shares with a market value of 46 million yuan [1]
明德生物收盘上涨1.75%,滚动市盈率129.01倍,总市值50.06亿元
Sou Hu Cai Jing· 2025-08-25 09:16
Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported a revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The sales gross margin stood at 16.37% [1] Market Position - The company's current stock price is 21.53 yuan, with a PE ratio of 129.01, significantly higher than the industry average of 55.91 and the industry median of 40.36 [2] - Mingde Biological's total market capitalization is 5.006 billion yuan [1][2] - As of the first quarter of 2025, there are 2 institutional investors holding shares in the company, with a total holding of 123,100 shares valued at 0.02 million yuan [1]
拱东医疗收盘下跌1.06%,滚动市盈率29.29倍,总市值45.09亿元
Sou Hu Cai Jing· 2025-08-22 11:22
Company Overview - Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, development, production, and sales of disposable medical consumables [1] - The main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - For Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - The net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The gross profit margin stood at 32.40% [1] Market Position - As of August 22, the company's stock closed at 20.45 yuan, down 1.06%, with a rolling PE ratio of 29.29 times [1] - The total market capitalization is 4.509 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Gongdong Medical at the 58th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, up by 735 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]
建发合诚收盘下跌1.30%,滚动市盈率25.99倍,总市值27.71亿元
Sou Hu Cai Jing· 2025-08-22 11:22
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Jianfa Heceng, which has a current stock price of 10.63 yuan and a rolling PE ratio of 25.99 times, significantly lower than the industry average of 69.14 times [1][2] - As of the latest half-year report in 2025, Jianfa Heceng achieved an operating income of 3.393 billion yuan, representing a year-on-year increase of 7.67%, and a net profit of 45.0448 million yuan, up 32.33% year-on-year, with a sales gross margin of 4.99% [1] - The company operates in six main business areas: surveying and design, project management, testing and inspection, construction, comprehensive maintenance, and engineering new materials, and has received several prestigious awards in the industry [1] Group 2 - Jianfa Heceng ranks 27th in the engineering consulting services industry based on PE ratio, with a total market capitalization of 2.771 billion yuan [1][2] - The company is held by four institutions, including two funds, with a total shareholding of 84.2411 million shares valued at 821 million yuan [1] - The industry average PE ratio is 69.14, while the median is 40.92, indicating that Jianfa Heceng's valuation is below both the average and median of its peers [2]
通源石油收盘下跌1.65%,滚动市盈率60.03倍,总市值31.48亿元
Sou Hu Cai Jing· 2025-08-22 09:29
8月22日,通源石油今日收盘5.35元,下跌1.65%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到60.03倍,总市值31.48亿元。 通源石油科技集团股份有限公司的主营业务是公司致力于为油气田开发提供全方位的解决方案和技术服 务。公司的主要产品是射孔销售及服务项目、其他油田服务。 最新一期业绩显示,2025年半年报,公司实现营业收入5.51亿元,同比0.03%;净利润3863.37万元,同 比11.31%,销售毛利率24.80%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10通源石油60.0356.582.1931.48亿行业平均 30.8731.663.61155.53亿行业中值36.9639.903.5051.64亿1海油发展10.6211.231.49410.67亿2中曼石油 12.0112.952.2193.99亿3海油工程12.1111.560.94249.81亿4金诚信19.4921.313.62337.53亿5中海油服 20.3021.931.54688.06亿6广东宏大27.2930.054.03269.80亿7中油工程34.7731.630.75200.99 ...
澳洋健康收盘上涨3.74%,滚动市盈率120.04倍,总市值34.00亿元
Sou Hu Cai Jing· 2025-08-21 08:45
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's stock closed at 4.44 yuan, with a PE ratio of 120.04, marking a new low in 48 days, and a total market capitalization of 3.4 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with its main products being medical services and pharmaceutical logistics [1] Group 2 - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.49 million yuan, down 39.82% [2] - The average PE ratio for the medical services industry is 49.07, with a median of 65.74, positioning Aoyang Health at 39th place within the industry [1][2] - The company has received various honors, including being ranked 32nd in the non-public hospital top 100 list and second among county-level non-public hospitals in China [1]
伟思医疗收盘下跌2.82%,滚动市盈率47.18倍,总市值53.52亿元
Sou Hu Cai Jing· 2025-08-20 11:34
Company Overview - Weisi Medical's closing price on August 20 was 55.88 yuan, down 2.82%, with a rolling PE ratio of 47.18 times and a total market value of 5.352 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 59.32 times and a median of 39.97 times, placing Weisi Medical at the 83rd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1] Industry Comparison - The PE ratios for other companies in the medical device sector range from 11.61 to 20.96, with Weisi Medical's PE ratio being higher than the industry average and median [2]